Although surufatinib showed activity following disease progression in both patients with epNET and pancreatic NET with a Ki‐67 >10%, disease‐specific activity in NET G3 was not reported.75, 76. This evidence concerns the gene MKI67 and pancreatic neuroendocrine tumor.